Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Researcher

Sophie Vanherrewege

Publications & Research Data

Awards & Distinctions

5 Results

2024

In-depth analysis of the HIV reservoir confirms effectiveness and safety of dolutegravir/lamivudine in a phase 4 randomized controlled switch trial (RUMBA)

Marie-Angélique De ScheerderSophie DegrooteMareva DelporteMaja KiselinovaWim TrypsteenLara VinckeEvelien De SmetBram Van Den EeckhoutLoic SchrooyenMaxime Verschoore et al.

A1 Journal Article in JOURNAL OF INFECTIOUS DISEASES

Staging of immuno-virological dynamics during acute HIV infection in a Belgian prospective cohort study

Jozefien De ClercqMarie-Angélique De ScheerderSophie VanherrewegeEls CaluweNathalie MoreelsDanny DeloozeAnnemieke DhondtMarc CoppensStefaan J. VandecasteeleSabine D. Allard et al.

A1 Journal Article in JOURNAL OF VIRUS ERADICATION

2022

Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting : a randomized placebo-controlled phase II trial

Els TobbackSophie DegrooteSabine BuysseLiesbeth DelesieLucas Van DoorenSophie VanherrewegeCyril BarbezangeVeronik HutseMarta RomanoIsabelle Thomas et al.

A1 Journal Article in INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Impact of switch towards 3TC/dolutegravir on the intact and total viral reservoir in the Rumba study

Evy BlommeWim TrypsteenMareva DelporteC. MucciniE. De SmetSophie DegrooteEls TobbackSophie VanherrewegeE. CaluweMarie-Angélique De Scheerder et al.

Understanding changes in metabolic parameters switching to 2DR or 3DR integrase strand inhibitors (InSTIs)

Sophie DegrooteSophie VanherrewegeEls TobbackE. CaluweLara VinckeEvy BlommeLinos VandekerckhoveMarie-Angélique De Scheerder